Suketu Upadhyay - Zimmer Biomet Chief Financial Officer, Executive Vice President
| ZBH Stock | USD 112.02 1.38 1.25% |
President
Mr. Suketu P. Upadhyay is appointed as Chief Financial Officer, Executive Vice President of the Company. He joins Zimmer Biomet from BristolMyers Squibb Company, where he has served as Senior Vice President, Global Financial Operations since November 2016. Before joining BristolMyers Squibb, he served as Executive Vice President, Chief Financial Officer of Endo International plc from September 2013 to November 2016. Prior to that, Mr. Upadhyay held leadership positions at Becton, Dickinson Company as Controller and Chief Accounting Officer and as Interim Chief Financial Officer. He also held leadership roles with Johnson Johnson and AstraZeneca. Mr. Upadhyay began his career with KPMG and has held the designations of Certified Public Accountant and Certified Management Accountant. since 2019.
| Age | 55 |
| Tenure | 5 years |
| Address | 345 East Main Street, Warsaw, IN, United States, 46580 |
| Phone | 574 373 3333 |
| Web | https://www.zimmerbiomet.com |
Suketu Upadhyay Latest Insider Activity
Tracking and analyzing the buying and selling activities of Suketu Upadhyay against Zimmer Biomet stock is an integral part of due diligence when investing in Zimmer Biomet. Suketu Upadhyay insider activity provides valuable insight into whether Zimmer Biomet is net buyers or sellers over its current business cycle. Note, Zimmer Biomet insiders must abide by specific rules, including filing SEC forms every time they buy or sell Zimmer Biomet'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Suketu Upadhyay over two weeks ago Disposition of 15948 shares by Suketu Upadhyay of Zimmer Biomet subject to Rule 16b-3 | ||
Suketu Upadhyay over two weeks ago Disposition of 15948 shares by Suketu Upadhyay of Zimmer Biomet subject to Rule 16b-3 |
Zimmer Biomet Management Efficiency
The company has Return on Asset of 0.0461 % which means that on every $100 spent on assets, it made $0.0461 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0871 %, implying that it generated $0.0871 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The Zimmer Biomet's current Return On Tangible Assets is estimated to increase to 0.18, while Return On Capital Employed is projected to decrease to 0.07. As of now, Zimmer Biomet's Fixed Asset Turnover is decreasing as compared to previous years. The Zimmer Biomet's current Asset Turnover is estimated to increase to 0.68, while Total Assets are projected to decrease to under 13.7 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Sean Salmon | Medtronic PLC | 59 | |
| Jared Watkin | Abbott Laboratories | 56 | |
| Paul Connolly | Smith Nephew SNATS | 56 | |
| Phil Cowdy | Smith Nephew SNATS | 53 | |
| Huimin Wang | Edwards Lifesciences Corp | 64 | |
| Vasant Padmanabhan | Smith Nephew SNATS | 57 | |
| Hubert Allen | Abbott Laboratories | 58 | |
| Catherine Szyman | Edwards Lifesciences Corp | 54 | |
| Richard Kuntz | Medtronic PLC | 63 | |
| JeanLuc Lemercier | Edwards Lifesciences Corp | 67 | |
| Carol Surface | Medtronic PLC | 54 | |
| Robert Hoedt | Medtronic PLC | 64 | |
| Larry Wood | Edwards Lifesciences Corp | 58 | |
| Bradley Cannon | Smith Nephew SNATS | 56 | |
| Geoffrey Martha | Medtronic PLC | 54 | |
| Joseph Manning | Abbott Laboratories | 55 | |
| Mark Gladwell | Smith Nephew SNATS | 44 | |
| Roger Bird | Abbott Laboratories | 63 | |
| Andrew Balo | DexCom Inc | 76 | |
| Frank Chan | Medtronic PLC | N/A | |
| Robert Funck | Abbott Laboratories | 63 | |
Management Performance
| Return On Equity | 0.0871 | ||||
| Return On Asset | 0.0461 |
Zimmer Biomet Holdings Leadership Team
Elected by the shareholders, the Zimmer Biomet's board of directors comprises two types of representatives: Zimmer Biomet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zimmer. The board's role is to monitor Zimmer Biomet's management team and ensure that shareholders' interests are well served. Zimmer Biomet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zimmer Biomet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sreelakshmi Kolli, Independent Director | ||
| Didier Deltort, President - Europe, Middle East and Africa | ||
| Carrie Nichol, Chief Accounting Officer, Vice President Controller | ||
| Arthur Higgins, Independent Director | ||
| Michael Michelson, Independent Director | ||
| Larry Glasscock, Independent Non-Executive Chairman of the Board | ||
| Nitin Goyal, Chief Science, Technology and Innovation Officer | ||
| Ellison Humphrey, Senior Vice President, Chief Transformation Officer | ||
| Chad JD, General VP | ||
| Derek Davis, Chief Accounting Officer, Vice President, Controller | ||
| Ivan Tornos, Group President - Global Businesses and Americas | ||
| Angela Main, Global VP | ||
| Wilfred Zuilen, President - Europe, Middle East and Africa | ||
| Suketu Upadhyay, Chief Financial Officer, Executive Vice President | ||
| Zeeshan Tariq, Senior Officer | ||
| Christopher Begley, Lead Independent Director | ||
| Bryan Hanson, Chairman of the Board, President, Chief Executive Officer | ||
| Sang Yi, President Asia Pacific | ||
| Betsy Bernard, Independent Director | ||
| Keri Mattox, Senior Vice President - Investor Relations, Chief Communications Officer | ||
| Maria Hilado, Independent Director | ||
| Rachel Ellingson, Senior Vice President Chief Strategy Officer, Executive Officer | ||
| Nitin MD, Technology Science | ||
| Chad Phipps, Senior Vice President, General Counsel, Secretary | ||
| Syed Jafry, Independent Director | ||
| Paul Stellato, Controller VP | ||
| Michael Farrell, Independent Director | ||
| Lori Winkler, Chief Human Resource Officer, Senior Vice President | ||
| Zachary CPA, Director Relations | ||
| David DeMartino, Senior Relations | ||
| Gail Boudreaux, Independent Director | ||
| Shaun Braun, Senior Officer | ||
| Robert Hagemann, Independent Director |
Zimmer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zimmer Biomet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0871 | ||||
| Return On Asset | 0.0461 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 28.3 B | ||||
| Shares Outstanding | 199.07 M | ||||
| Shares Owned By Insiders | 0.14 % | ||||
| Shares Owned By Institutions | 93.41 % | ||||
| Number Of Shares Shorted | 6.87 M | ||||
| Price To Earning | 77.41 X |
Currently Active Assets on Macroaxis
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.597 | Dividend Share 0.96 | Earnings Share 5.24 | Revenue Per Share 37.006 | Quarterly Revenue Growth 0.04 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.